RTA 744

DRUG3 trials

Sponsors

M.D. Anderson Cancer Center, Biogen

Conditions

Brain TumorGliomaLeptomeningeal CarcinomatosisLeukemiaLymphomaNeoplastic MeningitisSolid Tumor

Phase 1

RTA 744 Injection in Patients With Leptomeningeal Disease

TerminatedNCT00512460

M.D. Anderson Cancer CenterBrain Tumor, Leukemia, Lymphoma +2

Start: 2006-09-30End: 2010-03-31Updated: 2016-05-16

A Safety Study of RTA 744 in Patients With Recurrent High-Grade Gliomas

CompletedNCT00526812

Start: 2005-11-30Updated: 2025-05-28

A Safety Study of RTA 744 in Recurrent, Progressive or Refractory Neoplastic Meningitis

TerminatedNCT00527410

BiogenLeptomeningeal Carcinomatosis

Start: 2006-10-31Updated: 2025-05-30

Related Papers

Phase I Trial and Pharmacokinetic Study of Berubicin (RTA 744) in Patients with Recurrent or Refractory High-Grade Gliomas

Neuro-Oncology Advances2026-07-31